T. Rowe Price Associates’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $77.6M | Buy |
5,907,992
+565,648
| +11% | +$7.43M | 0.01% | 622 |
|
|
2025
Q1 | $76.8M | Sell |
5,342,344
-22,048
| -0.4% | -$317K | 0.01% | 604 |
|
|
2024
Q4 | $89.9M | Buy |
5,364,392
+685,371
| +15% | +$11.5M | 0.01% | 587 |
|
|
2024
Q3 | $74.8M | Buy |
4,679,021
+1,148,648
| +33% | +$18.4M | 0.01% | 633 |
|
|
2024
Q2 | $31.9M | Buy |
3,530,373
+572,294
| +19% | +$5.17M | ﹤0.01% | 844 |
|
|
2024
Q1 | $33.4M | Buy |
2,958,079
+418,615
| +16% | +$4.73M | ﹤0.01% | 825 |
|
|
2023
Q4 | $20.2M | Sell |
2,539,464
-9,670
| -0.4% | -$77K | ﹤0.01% | 950 |
|
|
2023
Q3 | $16.5M | Buy |
2,549,134
+185,923
| +8% | +$1.2M | ﹤0.01% | 958 |
|
|
2023
Q2 | $14.6M | Buy |
2,363,211
+49,778
| +2% | +$308K | ﹤0.01% | 1011 |
|
|
2023
Q1 | $8.91M | Sell |
2,313,433
-73,734
| -3% | -$284K | ﹤0.01% | 1079 |
|
|
2022
Q4 | $7.4M | Sell |
2,387,167
-58,816
| -2% | -$182K | ﹤0.01% | 1103 |
|
|
2022
Q3 | $9.83M | Sell |
2,445,983
-15,147
| -0.6% | -$60.9K | ﹤0.01% | 1067 |
|
|
2022
Q2 | $12M | Sell |
2,461,130
-67,453
| -3% | -$329K | ﹤0.01% | 1289 |
|
|
2022
Q1 | $22.7M | Buy |
2,528,583
+451,813
| +22% | +$4.05M | ﹤0.01% | 1201 |
|
|
2021
Q4 | $23.4M | Buy |
2,076,770
+58,897
| +3% | +$663K | ﹤0.01% | 1247 |
|
|
2021
Q3 | $33.1M | Buy |
2,017,873
+6,800
| +0.3% | +$112K | ﹤0.01% | 1157 |
|
|
2021
Q2 | $43.9M | Buy |
+2,011,073
| New | +$43.9M | ﹤0.01% | 1071 |
|